AMG 160; a half-life extended (HLE) bispecific T-cell engager (BITE®) antibody construct is discussed as is the future of immune therapy in CRPC.
Mark Goldman CPA
Hedge Fund Manager Erik Townsend
Elias Belhaddad
News in Slow French
Rohit Musale, CFA
AfterBuzz TV
Stephanie Laska
Gamut Podcast Network
Hidden Brain, Shankar Vedantam
Prarthana Khare
don't worry if you don't have an account with us, we'll create one
